JP2023545588A5 - - Google Patents

Info

Publication number
JP2023545588A5
JP2023545588A5 JP2023547753A JP2023547753A JP2023545588A5 JP 2023545588 A5 JP2023545588 A5 JP 2023545588A5 JP 2023547753 A JP2023547753 A JP 2023547753A JP 2023547753 A JP2023547753 A JP 2023547753A JP 2023545588 A5 JP2023545588 A5 JP 2023545588A5
Authority
JP
Japan
Prior art keywords
cancer
compound
compound according
none
apply
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023547753A
Other languages
English (en)
Japanese (ja)
Other versions
JP7850460B2 (ja
JP2023545588A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/078696 external-priority patent/WO2022079290A2/en
Publication of JP2023545588A publication Critical patent/JP2023545588A/ja
Publication of JP2023545588A5 publication Critical patent/JP2023545588A5/ja
Application granted granted Critical
Publication of JP7850460B2 publication Critical patent/JP7850460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547753A 2020-10-16 2021-10-15 ヘテロ環式カリンringユビキチンリガーゼ化合物及びその使用 Active JP7850460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20202417.0 2020-10-16
EP20202417 2020-10-16
PCT/EP2021/078696 WO2022079290A2 (en) 2020-10-16 2021-10-15 Cullin ring ubiquitin ligase compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2023545588A JP2023545588A (ja) 2023-10-30
JP2023545588A5 true JP2023545588A5 (cg-RX-API-DMAC7.html) 2024-11-08
JP7850460B2 JP7850460B2 (ja) 2026-04-23

Family

ID=72964476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547753A Active JP7850460B2 (ja) 2020-10-16 2021-10-15 ヘテロ環式カリンringユビキチンリガーゼ化合物及びその使用

Country Status (7)

Country Link
US (1) US20240132485A1 (cg-RX-API-DMAC7.html)
EP (1) EP4229037A2 (cg-RX-API-DMAC7.html)
JP (1) JP7850460B2 (cg-RX-API-DMAC7.html)
CN (1) CN116568671A (cg-RX-API-DMAC7.html)
AU (1) AU2021359129A1 (cg-RX-API-DMAC7.html)
CA (1) CA3194868A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022079290A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023203174A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN116003424B (zh) * 2022-11-30 2024-03-19 中国药科大学 Shp2与mek1双靶点抑制剂及其制备方法与应用
US20260209211A1 (en) * 2022-12-16 2026-07-23 Adlai Nortye Biopharma Co., Ltd. Cyclin k degrader and use thereof
KR20260074850A (ko) * 2023-08-18 2026-05-26 프록시젠 게엠베하 컬린 환 유비퀴틴 리가제 화합물로서 피라졸 화합물
WO2025104236A1 (en) * 2023-11-15 2025-05-22 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
CN119707806B (zh) * 2024-12-24 2025-12-12 河南师范大学 可见光催化不对称反应制备手性2-氮杂芳烃酰胺的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ATE248583T1 (de) 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
MXPA02001498A (es) 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
CA2392576A1 (en) * 1999-11-24 2001-05-31 Lingyan Wang .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
DZ3398A1 (fr) 2000-08-31 2002-03-07 Pfizer Prod Inc Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
DE60208630T2 (de) 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2008046919A2 (en) 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
JP4616237B2 (ja) 2006-11-07 2011-01-19 日本電信電話株式会社 シリコン化合物薄膜の形成方法
EP2121619A2 (en) * 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2309855A4 (en) * 2008-07-30 2012-06-27 Oncotherapy Science Inc BENZIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3-BETA INHIBITORS CONTAINING THE SAME
EP2599776B1 (en) * 2010-07-28 2014-10-15 Neugen Pharma Inc. Therapeutic agent for neurological diseases
GB2513403A (en) * 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
TN2016000542A1 (en) 2014-06-03 2018-04-04 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
GB2533421A (en) 2014-12-19 2016-06-22 Nordic Semiconductor Asa Integrated circuits
US10202376B2 (en) 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104447733B (zh) * 2015-01-05 2016-08-17 中国药科大学 1-苄基-2-吡咯啉酮-4-酰胺类化合物及其制备方法与应用
GB201501870D0 (en) * 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
WO2018129381A1 (en) * 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020523379A (ja) 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーEuropean Molecular Biology Laboratory 治療への使用のためのベンゾフランアミドおよびそれらの複素芳香族アナログ
WO2019046668A1 (en) 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
EP3746124A4 (en) * 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
AU2020214308A1 (en) * 2019-01-29 2021-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3128155C (en) * 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2

Similar Documents

Publication Publication Date Title
JP2016513660A5 (cg-RX-API-DMAC7.html)
JP2023520333A5 (cg-RX-API-DMAC7.html)
EP2959900B1 (en) Compound for treatment of cancer
JP2021519783A5 (cg-RX-API-DMAC7.html)
CN114430741A (zh) Egfr抑制剂、组合物及其制备方法
JP2021518441A5 (cg-RX-API-DMAC7.html)
JP2021535207A5 (cg-RX-API-DMAC7.html)
JP2023530231A5 (cg-RX-API-DMAC7.html)
JP2008535903A5 (cg-RX-API-DMAC7.html)
JP2008528467A5 (cg-RX-API-DMAC7.html)
JPWO2020085493A5 (cg-RX-API-DMAC7.html)
JP2014517017A5 (ja) 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用
CA2522435A1 (en) Inhibitors of akt activity
JP2012510989A5 (cg-RX-API-DMAC7.html)
JP2022500383A5 (cg-RX-API-DMAC7.html)
JP2014506585A (ja) キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
JP2025502377A5 (cg-RX-API-DMAC7.html)
JP2006515858A5 (cg-RX-API-DMAC7.html)
JP2009543771A5 (cg-RX-API-DMAC7.html)
JP2023531709A5 (cg-RX-API-DMAC7.html)
CA2617991A1 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP2024526984A5 (cg-RX-API-DMAC7.html)
JP2022533958A5 (cg-RX-API-DMAC7.html)
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
JP2023535790A5 (cg-RX-API-DMAC7.html)